Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
How does one assess and monitor patients with systemic lupus erythematosus in daily clinical practice?
  • Publication Type:
    Journal article
  • Publication Sub Type:
  • Authors:
    Haq I, Isenberg DA
  • Publication date:
  • Pagination:
    181, 194
  • Journal:
    Best Practice and Research Clinical Rheumatology
  • Volume:
  • Issue:
  • Print ISSN:
  • Keywords:
    activity, assessment, autoimmune, CHAPTER, clinical, Clinical assessment, Clinical practice, Clinical trial, Clinical Trials, CLINICAL-TRIAL, CLINICAL-TRIALS, COMPLEX, COMPLEXES, complications, Damage, disease, DO, flare, health, Health Status, HEALTH-STATUS, IM, LA, Lupus, Lupus Erythematosus, Systemic, MANIFESTATIONS, May, MONITOR, Monitoring, Physiologic, Other, Patient, patients, Physician's Practice Patterns, physiopathology, practice, Problems, Quality of Life, REMISSION, reversible, Review, rheumatic disease, Setting, SLE, SYSTEMIC, SYSTEMIC LUPUS ERYTHEMATOSUS, SYSTEMIC-LUPUS-ERYTHEMATOSUS, THERAPIES, therapy, Time Factors, TRIAL, TRIALS, Use
  • Notes:
    UI - 22037546 DA - 20020603 IS - 1521-6942 LA - eng PT - Journal Article PT - Review PT - Review, Tutorial SB - IM
Systemic lupus erythematosus (SLE) is a multisystem autoimmune rheumatic disease (ARD) characterized by flares and remissions. SLE has protean and often complex manifestations, necessitating careful clinical assessment. However, it is important to remember that not all clinical problems reported by a lupus patient are due to the disease. Some may be a consequence of therapy and others may be unrelated to lupus. Therefore it is important to understand the totality of the effect of the disease on the patient. In order to do this measures are needed which distinguish current, potentially reversible disease activity, permanent organ damage and the effect of the disease on the patients' health status. Several measures are in current use in clinical trials, but not all are suitable for use in the routine clinical setting. This chapter discusses the current measures available to assess disease activity and damage in SLE
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by